Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunome ( (IMNM) ) has issued an update.
On December 16, 2025, Immunome announced the pricing of a follow-on public offering of 18,625,000 shares of common stock at $21.50 per share, expected to generate approximately $400 million in gross proceeds. The offering, closing on December 18, 2025, supports Immunome’s market activities and reinforces its strategic push in advancing its oncology-focused initiatives, including its innovative therapy pipeline.
The most recent analyst rating on (IMNM) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Immunome stock, see the IMNM Stock Forecast page.
Spark’s Take on IMNM Stock
According to Spark, TipRanks’ AI Analyst, IMNM is a Neutral.
Immunome’s stock score is primarily influenced by its challenging financial performance, with significant losses impacting profitability. However, the technical analysis indicates strong bullish momentum, which is a positive factor. The valuation is negatively impacted by the negative P/E ratio and lack of dividend yield.
To see Spark’s full report on IMNM stock, click here.
More about Immunome
Immunome, Inc. is a clinical-stage biotechnology company specializing in developing first-in-class and best-in-class targeted therapies for oncology. Its portfolio includes innovative treatments like antibody-drug conjugates (ADCs), a gamma secretase inhibitor (GSI) in late clinical stage, radiotherapy treatments targeting specific markers, and a range of early-stage ADCs aimed at solid tumor targets.
Average Trading Volume: 1,675,674
Technical Sentiment Signal: Buy
Current Market Cap: $2.15B
For an in-depth examination of IMNM stock, go to TipRanks’ Overview page.